Money Moves is a column where we chart the funding raises of tech companies across the region. Have a tip? Email us at dc@technical.ly.
Corsha, a DC-based security company focused on API (application programming interface) security, just nabbed $12 million in a Series A.
The round was led by Ten Eleven Ventures and Razor’s Edge Ventures, with additional participation from 1843 Capital. The company did not specify what the funds would be used for.
Corsha was cofounded by Chris Simkins and Anusha Iyer in 2018. According to the founders, the company’s technology creates one-time use and multifactor authentication credentials through a zero-trust platform for public, private and hybrid cloud environments. According to a statement, the startup offers an identity-first approach to API security, creating an extra layer of protection in service-to-service communication.
“The greater we automate our application development and deployment processes, the more the risk shifts from human to machine,” Simkins said in the statement. “It’s more important than ever to have clear visibility into the machines that are accessing APIs and be able to seamlessly control access.”
DC virtual interpreting platform Jeenie just raised $9.3 million in a Series A, the company announced last week. Transformation Capital led the round.
Jeenie is a platform for clinicians and patients for virtual interpretation. Through a smartphone, tablet or third-party integrations, patients and providers can take part in a live video or audio call with interpreters in over 300 languages.
According to Jeenie, the fresh funds value the company at approximately $34 million and further affirm the need for its technology and innovative solutions in healthcare. The funds, Jeenie said, will be put towards expanding its operations and business reach.
“Together with our new partners at Transformation Capital, we will bring healthcare in the U.S. one step closer to a future of equity and access for all patients, no matter what language they speak,” CEO and cofounder Kristen Brecht Baker wrote in a Linkedin post announcing the news. “I am beyond proud of the Jeenie team that has brought us to this pivotal moment and accomplished so much. I look forward to the rewarding and prosperous journey we are all on together.”
Gaithersburg, Maryland-based biotech company Adaptive Phage Therapeutics added a new investor to its $40.75 million Series B round.
Adaptive Phage is a company in a clinical trial stage that was created to advance therapies and treatments for multi-drug-resistant infections. Since its founding, the company has already raised over $100 million in a combination of awards and equity funding.
“We are very pleased to welcome the AMR Action Fund as an investor,” said CEO and cofounder Greg Merril in a statement. “In addition to their capital, the AMR Action Fund adds significant strategic value, including advisory and scientific support. We believe AMR Action Fund will be an ideal partner to help progress and accelerate APT’s mission to provide an effective therapeutic response to the global rise of antimicrobial-resistant infections.”